Close Menu

Investment in China

Merck isn't the first pharmaceutical company to invest in research in China, but it sure is spending a lot more, says ScienceInsider's Hao Xin. The company says it plans to spend about $1.5 billion on R&D in China over the next five years, starting with a staff of 260 in Beijing. Merck already has a commercial headquarters in Shanghai and has built manufacturing facilities in other parts of China, Xin says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.